Axon Enterprise, Inc. filings document operating results and corporate actions for a public safety technology company with Software & Services and Connected Devices activities. Form 8-K reports include shareholder letters on financial results and outlooks, product demand across TASER devices, Axon Body cameras, Axon Evidence, AI products, counter-drone offerings and real-time operations, as well as material-event disclosures tied to capital structure.
Proxy materials cover board composition, shareholder meeting matters, executive compensation and equity awards. Other 8-K and 8-K/A filings record director election updates and the redemption and settlement of 0.50% convertible senior notes due 2027, including the disclosure that no convertible notes remained outstanding after the redemptions and conversions.
Patrick W. Smith, Axon CEO and director, reported multiple open-market sales of common stock executed pursuant to a Rule 10b5-1 trading plan adopted May 12, 2025. The Form 4 lists 16 separate sales on 08/11/2025 totaling 10,000 shares executed in multiple trades with reported weighted-average prices by tranche. Reported per-share execution ranges span approximately $821.50 to $839.11. After the reported transactions the filing shows the reporting person beneficially owned 3,053,982 shares of Axon.
The filing discloses the trades were made under a written 10b5-1 plan and provides weighted-average sale prices for each block; the submission is a routine insider disclosure of securities dispositions and the specific trade execution details are available upon request to the SEC staff, issuer or security holders per the filer’s statement.
Joshua Isner, an officer (President) of Axon Enterprise, reported multiple sales of the company’s common stock executed on 08/07/2025. The Form 4 lists five sale tranches that together total 2,500 shares sold, with reported weighted-average sale prices of $867.4875, $868.50, $869.7092, $871.2756 and $872.1513, and disclosed execution price ranges approximately $867.15 to $872.34.
After these transactions the reporting person is shown as directly owning 266,235 shares. No derivative securities were reported and the filer offers to provide full trade-level details to the SEC or security holders upon request.
Caitlin E. Kalinowski, identified as a director of Axon Enterprise (AXON), reported two separate sales of common stock on 08/07/2025 totaling 580 shares.
The filing shows a sale of 476 shares at a weighted-average price of $870.7414 and a sale of 104 shares at a weighted-average price of $872.0066. The two report lines list beneficial ownership amounts of 4,799 and 4,695 shares following the respective transactions. The Form 4 was executed through an attorney-in-fact and discloses the transaction details and weighted-average prices without additional commentary.
In this Form 144 notice for Axon Enterprise, Inc., the filer reports an intended sale of 10,000 shares of common stock through UBS Financial Services on Nasdaq with an aggregate market value of $8,428,900 and an approximate sale date of 08/11/2025. The shares were acquired on 11/15/2021 via an option exercise and paid in cash. The filing lists 78,504,440 shares outstanding, so the proposed sale represents about 0.0127% of outstanding shares.
The form shows no securities sold by the filer in the past three months and includes the standard Rule 144 representation that the filer does not possess undisclosed material adverse information. A broker is named and the transaction mechanics (option exercise, cash payment) are disclosed.
Axon Enterprise, Inc. (AXON) – Form 4 insider transaction summary: President Joshua Isner reported two transactions involving AXON common stock. On 16-Jun-2025, 680 shares were disposed under transaction code F (shares withheld to cover income-tax obligations triggered by restricted stock unit (RSU) vesting) at a price of $780.63 per share. On 17-Jun-2025, Isner sold 905 shares in the open market at $776.39 per share under a pre-arranged Rule 10b5-1 trading plan adopted on 21-Aug-2024.
Following these actions, Isner’s direct beneficial ownership declined from 270,320 shares to 268,735 shares, a reduction of roughly 0.6 % of his total position and an immaterial fraction of Axon’s ~74 million shares outstanding. No derivative securities were involved and no new options were granted or exercised. The filing indicates routine tax withholding and modest portfolio diversification rather than a strategic divestiture. Because the sales were both limited in size and executed under a 10b5-1 plan, the market impact is expected to be neutral to modestly negative.